Clinical trials
Cancer Recurrence clinical trials
Below are recruiting cancer recurrence clinical trials, each written for real people, not researchers. We’re tracking 690 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07185165RecruitingPhase 2
PET Scan for Prostate Cancer Recurrence After Focal Therapy
This study uses a special PET/CT scan (Flotufolastat F 18) to look for leftover or returning prostate cancer after you've had a targeted treatment called focal therapy. The goal is to see if the scan can help find cancer that might need further treatment.
Los Angeles, CaliforniaAges 18–90 - NCT06889649RecruitingPhase 2
SBRT plus immunotherapy and targeted therapy for kidney cancer
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT07506239Recruiting
Laser therapy for low-grade brain tumors in young people
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
San Francisco, CaliforniaAges 2–25 - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Birmingham, AlabamaAges Any age - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT06651580Recruiting
Gene study for kids with pancreas problems
This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.
Los Angeles, CaliforniaAges Up to 17 years - NCT07439913Enrolling by invitation
Predicting cancer return and bladder control after robot prostate surgery
This study looks at factors that can predict whether prostate cancer will come back in the 10 years after robot-assisted prostate removal surgery, and how well bladder control (urinary continence) recovers. It helps doctors understand which patients might do better long-term.
Banská BystricaAges Any age - NCT05929365Recruiting
Test genetic marker tracking to find returning colon polyps
This study looks at stool or tissue DNA changes (called mutation analysis) plus colonoscopy findings to detect whether colon polyps come back. It may help catch recurrent colorectal lesions earlier during surveillance after a large polyp was removed.
PragueAges 18–75 - NCT07611266Recruiting
Predicting colorectal adenoma recurrence using combined medicine approach
This study helps predict which patients with colorectal adenomas (pre-cancerous growths) are at higher risk of them coming back or turning into cancer. Researchers will use both Western medical tests and Traditional Chinese Medicine patterns to create a prediction tool that may guide your follow-up care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT07053033RecruitingPhase 2
Laser surgery or surgery plus second radiation for recurrent brain tumors
This trial is testing whether a second, precise dose of radiation to the brain, after a tumor has been removed or treated with a laser, can help people with recurrent brain metastases. It's for patients whose brain tumors have come back after prior radiation therapy.
Houston, TexasAges 18 years+ - NCT00412594RecruitingPhase 2
Cladribine plus rituximab for hairy cell leukemia
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
Houston, TexasAges 18 years+ - NCT07441499Recruiting
Detecting bladder cancer recurrence with a blood test
This study uses a blood test to find and monitor urothelial cancer (a type of bladder cancer) and to watch for signs it may come back. It may help patients and doctors make better decisions about follow-up care.
TianjinAges 18 years+ - NCT07632339RecruitingPhase 2
New drug combination for recurrent head and neck cancer
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT05059678Recruiting
Parenting support for families coping with advanced cancer
This study tests a parenting support program for adults who are living with an advanced solid cancer diagnosis and are actively treating it. It may help you and your child’s other parent/caregiver with coping and parenting during this stressful time.
Houston, TexasAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+
Hear when a new Cancer Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer recurrence?
- Yes. Clin2 currently lists 690 recruiting cancer recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.